Key result
Indolmycin competitively inhibits prokaryotic tryptophanyl-tRNA ligase, sparing eukaryotes.
Why the study?
Indolmycin's selective inhibition of prokaryotic tryptophanyl-tRNA ligase compared to eukaryotic systems was investigated in vitro.
null
null
Answers are grounded in this paper and cite their sources.
Indolmycin selectively inhibits prokaryotic tryptophanyl-tRNA ligase by competing with tryptophan, demonstrating its mechanism of action as an antibiotic.
Indolmycin specifically prevents the formation of tryptophanyl-tRNA in a prokaryotic system in vitro using Escherichia coli enzymes. However, the drug has little effect in an eukaryotic system in vitro (rat liver enzymes). Analysis of the type of inhibition revealed that indolmycin competes with tryptophan as a pure competitive inhibitor of prokaryotic tryptophanyl-tRNA ligase.
No takes yet. Share an insight, caveat, or question.
Werner et al. (1976) studied this question. Indolmycin acts as a pure competitive inhibitor of prokaryotic tryptophanyl-tRNA ligase, specifically preventing tryptophanyl-tRNA formation with little effect on eukaryotic systems.
Synapse has enriched 10 related papers. Consider them for comparative context: